BridgeMD
Tests treatment safety and results for Giant Cell Tumor of Bone
Official title Efficacy of ICG-based NIR Imaging in Intralesional Curettage of Giant Cell Tumors of Bone in Limbs: a Prospective, Single-center, Single-arm, Open Study
ClinicalTrials.gov ID: NCT06647901
What this study is testing
What is ICG (Indocyanine Green)?
ICG (Indocyanine Green) is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for giant cell tumor of bone.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- ICG fluorescence imaging will be applied during the intralesional curettage of giant cell tumor of bone in the limbs. This study aims to preliminarily explore whether ICG fluorescent-guided curettage could find small residual tumors and reduce the recurrence rate of tumor.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 65
You may be able to join if
- . Aged 18-65.
- Biopsy confirmed giant cell tumor of bone.
- The lesions located in the limbs.
- This operation is the initial treatment.
- Denosumab and diphosphonates are not used before surgery.
You likely can't join if
- . Known allergy to iodine contrast, indocyanine green or bone cement.
- . Severe hepatic and renal insufficiency.
- . During pregnancy or lactation.
- . Have other malignant tumors and are receiving related medical treatment.
See the full eligibility criteria
- . Aged 18-65.
- Biopsy confirmed giant cell tumor of bone.
- The lesions located in the limbs.
- This operation is the initial treatment.
- Denosumab and diphosphonates are not used before surgery.
- Planned operation is intralesional curettage and filling bone defects with bone cement.
- Preoperative bone scan and thin layer (layer thickness ≤3.5mm) chest CT plain scan confirmed that the lesion is a single occurrence without metastasis.
- people fully understand the benefits and risks of this experiment and are still willing to participate and sign the informed consent.
- . Known allergy to iodine contrast, indocyanine green or bone cement.
- . Severe hepatic and renal insufficiency.
- . During pregnancy or lactation.
- . Have other malignant tumors and are receiving related medical treatment.
The study team makes the final eligibility decision.
Where it's taking place
- Beijing, Beijing Municipality, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 65 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Beijing, Beijing Municipality, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.